# US 2021/0330717 A1 · Methods for Treating Ulcerative Colitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330717 A1
- Document ID: US20210330717A1
- Status: Published application
- Kind: A1
- Application number: 17/367,056
- Filed: 2021-07-02
- Published: 2021-10-28
- Earliest claimed: 2016-08-03
- Assignees: Finch Therapeutics Holdings LLC
- Applicants: Finch Therapeutics Holdings LLC
- Inventors: Thomas Julius BORODY
- Web page: https://patentgrep.com/patent/US20210330717A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/37: Digestive system
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.

## Claims

### Claim 1

A method for treating ulcerative colitis (UC) in a subject in need thereof comprising treating said subject with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 4 weeks and at least once per week, wherein said treatment regimen is capable of achieving a primary outcome rate of at least two fold higher relative to a primary outcome rate from placebo, wherein said primary outcome is defined as a steroid-free clinical remission and endoscopic remission or response at the end of said treatment regimen, wherein said clinical remission is defined as a total Mayo score of 2 or lower with all sub-scores of 1 or lower, wherein said endoscopic remission or response is defined as a reduction of at least 1 point from baseline in Mayo endoscopy score.

### Claim 2 (depends on 1)

The method of claim 1, wherein said treatment regimen a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week.

### Claim 3 (depends on 2)

The method of claim 2, wherein said treatment regimen is capable of achieving a primary outcome rate of at least 25%.

### Claim 4 (depends on 2)

The method of claim 2, wherein said treatment regimen is capable of achieving a clinical remission sustaining rate of at least 40% at 8 weeks after the completion of said treatment regimen.

### Claim 5 (depends on 1)

The method of claim 1, wherein said treatment regimen is capable of achieving a steroid-free clinical remission rate of at least two fold higher relative to a steroid-free clinical remission rate from placebo, wherein said clinical remission is defined as a combined Mayo score of 1 or lower for rectal bleeding and stool frequency.

### Claim 6 (depends on 5)

The method of claim 5, wherein said treatment regimen is capable of achieving a steroid-free clinical remission rate of at least 40%.

### Claim 7 (depends on 1)

The method of claim 1, wherein said treatment regimen is capable of achieving a steroid-free clinical response rate of at least two fold higher relative to a steroid-free clinical response rate from placebo, wherein said clinical response is defined as a total Mayo score decrease of 3 or higher or a 50% or higher reduction from baseline in combined score for rectal bleeding and stool frequency.

### Claim 8 (depends on 7)

The method of claim 7, wherein said treatment regimen is capable of achieving a steroid-free clinical response rate of at least 50%.

### Claim 9 (depends on 1)

The method of claim 1, wherein said treatment regimen is capable of achieving an endoscopic response rate of at least two fold higher relative to an endoscopic response rate from placebo, wherein said endoscopic response is defined as a total UCEIS score decrease of 3 or higher or a 50% or higher reduction from baseline.

### Claim 10 (depends on 9)

The method of claim 9, wherein said treatment regimen is capable of achieving an endoscopic response rate of at least 30%.

### Claim 11 (depends on 1)

The method of claim 1, wherein said method further comprises determining said subject's baseline gut bacterial diversity.

### Claim 12 (depends on 1)

The method of claim 1, wherein said method further comprises determining the level of one or more bacteria selected from the group consisting of Fusobacterium, Sutterella, Barnesiella, Parabacteroides, Clostridium IV, Ruminococcus, Blautia, Dorea, Ruminococcus2, and Clostridium XVIII in said subject's gut.

### Claim 13 (depends on 1)

The method of claim 1, wherein said pharmaceutical composition comprises a fecal microbiota preparation.

### Claim 14 (depends on 1)

The method of claim 1, wherein said subject exhibits a Mayo score of at least 4 prior to said treating.

### Claim 15

A method for treating ulcerative colitis (UC) in a subject in need thereof and exhibiting a Mayo endoscopy score of 3 or lower, said method comprising administering to said subject a pharmaceutical composition comprising live non-pathogenic fecal bacteria.

### Claim 16 (depends on 15)

The method of claim 15, wherein said administering is following a treatment regimen of at least 8 weeks at a frequency selected from the group consisting of daily, at least once per week, at least twice per week, and at least three times per week.

### Claim 17 (depends on 16)

The method of claim 16, wherein said subject is capable of achieving a primary outcome at the end of said treatment regimen, wherein said primary outcome is defined as a steroid-free clinical remission and endoscopic remission or response at the end of said treatment regimen, wherein said steroid-free clinical remission is defined as a total Mayo score of 2 or lower with all sub-scores of 1 or lower, wherein said endoscopic remission or response is defined as a reduction of at least 1 point from baseline in endoscopy score.

### Claim 18

A method for treating ulcerative colitis (UC) in a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising live non-pathogenic fecal bacteria, wherein said subject has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.

### Claim 19 (depends on 18)

The method of claim 18, wherein said administering is following a regimen of at least 8 weeks and at least three times per week.

### Claim 20 (depends on 19)

The method of claim 19, wherein said subject is capable of achieving a primary outcome at the end of said regimen, wherein said primary outcome is defined as a steroid-free clinical remission and endoscopic remission or response at the end of said treatment regimen, wherein said steroid-free clinical remission is defined as a total Mayo score of 2 or lower with all sub-scores of 1 or lower, wherein said endoscopic remission or response is defined as a reduction of at least 1 point from baseline in endoscopy score.
